Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy

AIDS

Volumn 24, Issue 11, 2010, Pages 1717-1726

  Grunfeld, Carl ^a   Saag, Michael ^b   Cofrancesco, Joseph ^c   Lewis, Cora Elizabeth ^d   Kronmal, Richard ^e   Heymsfield, Steven ^f   Tien, Phyllis C ^a   Bacchetti, Peter ^a   Shlipak, Michael ^a   Scherzer, Rebecca ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ALABAMA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

body composition; fat redistribution; HIV infection; lipoatrophy; lipodystrophy; lipohypertrophy; visceral obesity

Indexed keywords

STAVUDINE; ZIDOVUDINE;

ABDOMINAL SUBCUTANEOUS FAT; ADIPOSE TISSUE; ADULT; ARTICLE; BODY FAT DISTRIBUTION; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAABDOMINAL FAT; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; WHOLE BODY MRI;

ADIPOSE TISSUE; ADULT; ANTI-HIV AGENTS; BODY COMPOSITION; BODY FAT DISTRIBUTION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LEG; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; STAVUDINE; SUBCUTANEOUS FAT;

EID: 77954348815     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833ac7a2     Document Type: Article

References (33)

1. Grunfeld C, Kotler DP, Arnett DK, Falutz JM, Haffner SM, Hruz P, et al. Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation 2008; 118:e20-e28.
2. The Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40:121-131.
3. The Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr 2006; 42:562-571.
4. Lewis CE, Jacobs DR Jr, McCreath H, Kiefe CI, Schreiner PJ, Smith DE, Williams OD. Weight gain continues in the 1990s: 10-year trends in weight and overweight from the CARDIA study. Coronary Artery Risk Development in Young Adults. Am J Epidemiol 2000; 151:1172-1181.
5. Li C, Ford ES, Zhao G, Balluz LS, Giles WH. Estimates of body composition with dual-energy X-ray absorptiometry in adults. Am J Clin Nutr 2009; 90:1457-1465.
6. Hansen BR, Haugaard SB, Iversen J, Nielsen JO, Andersen O. Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review. Scand J Infect Dis 2004; 36:244-253.
7. Barragan P, Fisac C, Podzamczer D. Switching strategies to improve lipid profile and morphologic changes. AIDS Rev 2006; 8:191-203.
8. Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18:1029-1036.
9. Ribera E, Paradineiro JC, Curran A, Sauleda S, Garcia-Arumi E, Castella E, et al. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study). HIV Clin Trials 2008; 9:407-417.
10. Valantin MA, Lanoy E, Bentata M, Kalmykova O, Boutekadjirt A, Allavena C, et al. Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial. HIV Med 2008; 9:625-635.
11. Tavassoli N, Bagheri H, Sommet A, Delpierre C, Marion-Latard F, Massip P, et al. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy X-ray absorptiome-try. Pharmacotherapy 2006; 26:154-161.
12. Tebas P, Zhang J, Yarasheski K, Evans S, Fischl MA, Shevitz A, et al. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). J Acquir Immune Defic Syndr 2007; 45:193-200.
13. Madruga JR, Cassetti I, Suleiman JM, Etzel A, Zhong L, Holmes CB, et al. The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy. HIV Clin Trials 2007; 8:381-390. (Pubitemid 350305212)
14. Tien PC, Schneider MF, Cole SR, Justman JE, French AL, Young M, et al. Relation of stavudine discontinuation to anthropo-metric changes among HIV-infected women. J Acquir Immune Defic Syndr 2007; 44:43-48.
15. Brown T, Wang Z, Chu H, Palella FJ, Kingsley L, Witt MD, Dobs AS. Longitudinal anthropometric changes in HIV-infected and HIV-uninfected men. J Acquir Immune Defic Syndr 2006; 43:356-362.
16. Tien PC, Benson C, Zolopa AR, Sidney S, Osmond D, Grunfeld C. The Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM): methods, design, and sample characteristics. Am J Epidemiol 2006; 163:860-869.
17. Friedman GD, Cutter GR, Donahue RP, Hughes GH, Hulley SB, Jacobs DR Jr, et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 1988; 41:1105-1116.
18. Cockerham L, Scherzer R, Zolopa A, Rimland D, Lewis CE, Bacchetti P, et al. Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. J Acquir Immune Defic Syndr 2010; 53:102-106.
19. Gallagher D, Belmonte D, Deurenberg P, Wang Z, Krasnow N, Pi-Sunyer FX, Heymsfield SB. Organ-tissue mass measurement allows modeling of REE and metabolically active tissue mass. Am J Physiol 1998; 275:E249-E258.
20. Shen W, WangZ, Tang H, Heshka S, PunyanityaM, Zhu S, et al. Volume estimates by imaging methods: model comparisons with visible woman as the reference. Obes Res 2003; 11:217-225.
21. Sidney S, Jacobs DR Jr, Haskell WL, Armstrong MA, Dimicco A, Oberman A, et al. Comparison of two methods of assessing physical activity in the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Epidemiol 1991; 133:1231-1245.
22. Hoegerman GS, Lewis CE, Flack J, Raczynski JM, Caveny J, Gardin JM. Lack of association of recreational cocaine and alcohol use with left ventricular mass in young adults. The Coronary Artery Risk Development in Young Adults (CARDIA) study. J Am Coll Cardiol 1995; 25:895-900.
23. Hastie T, Tibshirani R, editors. Generalized additive models. London: Chapman and Hall; 1990.
24. Efron B, Tibshirani R. An introduction to the bootstrap. London: Chapman and Hall; 1993. pp. 178-188, 214-178, 398-403.
25. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res 1999; 8:3-15.
26. Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 2000; 56:779-788.
27. Kosmiski LA, Bacchetti P, Kotler DP, Heymsfield SB, Lewis CE, Shlipak MG, et al. Relationship of fat distribution with adipo-kines in human immunodeficiency virus infection. J Clin Endocrinol Metab 2008; 93:216-224.
28. Scherzer R, Shen W, Bacchetti P, Kotler D, Lewis CE, Shlipak MG, et al. Comparison of dual-energy X-ray absorptiometry and magnetic resonance imaging-measured adipose tissue depots in HIV-infected and control subjects. Am J Clin Nutr 2008; 88:1088-1096.
29. Hill JO, Sidney S, Lewis CE, Tolan K, Scherzinger AL, Stamm ER. Racial differences in amounts of visceral adipose tissue in young adults: the CARDIA (Coronary Artery Risk Development in Young Adults) study. Am J Clin Nutr 1999; 69:381-387.
30. Hooker DJ, Cherry CL. Apoptosis: a clinically useful measure of antiretroviral drug toxicity? Expert Opin Drug Metab Toxicol 2009; 5:1543-1553.
31. CurrierJ, ScherzerR, BacchettiP, Heymsfield S, Lee D, Sidney S, Tien PC. Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women. J Acquir Immune Defic Syndr 2008; 48:35-43. (Pubitemid 351600850)
32. Wohl D, Scherzer R, Heymsfield S, Simberkoff M, Sidney S, Bacchetti P, Grunfeld C. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr 2008; 48;44-52. (Pubitemid 351600858)
33. Crane HM, Grunfeld C, Harrington RD, Uldall KK, Ciecha-nowski PS, Kitahata MM. Lipoatrophy among HIV-infected patients is associated with higher levels of depression than lipohypertrophy. HIV Med 2008; 9:780-786.